The response of bone turnover markers to lasofoxifene: The PEARL trial

被引:2
作者
Eastell, R. [1 ]
Reid, D. M. [2 ]
Vukicevic, S. [3 ]
Delmas, P. D. [4 ]
Thompson, J. [5 ]
Thompson, D. D. [6 ]
Cummings, S. R. [7 ,8 ]
机构
[1] Univ Sheffield, Acad Unit Bone Metab, Sheffield, S Yorkshire, England
[2] Univ Aberdeen, Div Appl Med, Aberdeen, Scotland
[3] Univ Zagreb, Sch Med, Lab Mineralized Tissue, Zagreb 41001, Croatia
[4] Univ Lyon, INSERM, Res Unit 831, Lyoh, France
[5] Pfizer Global Res & Dev, Clin Biostat, New London, CT USA
[6] Pfizer Global Res & Dev, Groton Clin Res, New London, CT USA
[7] Calif Pacific Med Ctr, Res Inst, San Francisco Coordinating Ctr, San Francisco, CA USA
[8] Univ Calif San Francisco, San Francisco, CA 94143 USA
关键词
D O I
10.1016/j.bone.2009.03.108
中图分类号
R5 [内科学];
学科分类号
1002 ; 100201 ;
摘要
引用
收藏
页码:S243 / S244
页数:2
相关论文
共 1 条
[1]   Response to therapy with once-weekly alendronate 70 mg compared to once-weekly risedronate 35 mg in the treatment of postmenopausal osteoporosis [J].
Sebba, AI ;
Bonnick, SL ;
Kagan, R ;
Thompson, DE ;
Skalky, CS ;
Chen, EL ;
de Papp, AE .
CURRENT MEDICAL RESEARCH AND OPINION, 2004, 20 (12) :2031-2041